intravenous cangrelor beneficial for acute ischemic stroke:Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-26 03:30 GMT   |   Update On 2023-10-10 10:57 GMT

A small dose of intravenous cangrelor is as good as oral antiplatelets in acute ischemic stroke, suggests a study published in the Frontiers of Neurology. Neuro-interventional procedures in acute ischemic stroke often require immediate antiplatelet therapy in the cases of acute stenting and occasionally re-occluding vessels. Intravenous cangrelor is a P2Y12 receptor antagonist with a...

Login or Register to read the full article

A small dose of intravenous cangrelor is as good as oral antiplatelets in acute ischemic stroke, suggests a study published in the Frontiers of Neurology.

Neuro-interventional procedures in acute ischemic stroke often require immediate antiplatelet therapy in the cases of acute stenting and occasionally re-occluding vessels. Intravenous cangrelor is a P2Y12 receptor antagonist with a short onset and quick offset.

A study was conducted by a group of researchers from the U.S.A. to evaluate the safety and efficacy of intravenous cangrelor in patients with acute ischemic stroke requiring urgent antiplatelet effect.

Patients who received intravenous cangrelor intra-procedurally during acute ischemic stroke treatment were identified from a prospectively collected database. Cangrelor was administered as a bolus of 15 mcg/kg, followed by an infusion rate of 2 mcg/kg/min. A historical control group consisting of anterior circulation tandem occlusions was used to compare to patients with similar lesions who received intravenous cangrelor.

Outcomes of interest included in-stent thrombosis, thromboembolic complications, intracranial haemorrhage, and functional outcomes at 90 days.

The results of the study are as follows:

  • Twelve patients received intravenous cangrelor for acute ischemic stroke between October 2018 and April 2020 at a comprehensive stroke centre.
  • Eleven patients had intra or extracranial stenting performed, which included two posterior circulation lesions.
  • No cases of symptomatic intracranial haemorrhage were reported.
  • At 90-day follow-up, two patients had died, and 10 had a good functional outcome.
  • Patients with anterior circulation tandem occlusions who received cangrelor and those who received dual antiplatelets orally had similar radiographic and clinical outcomes.

Thus, the researchers concluded that low dose intravenous cangrelor is similar in safety and efficacy to oral antiplatelets in acute ischemic stroke in a small case series. Larger prospective studies on the efficacy, safety, and effect on procedure times of intravenous cangrelor in neuro intervention is warranted.

Reference:

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series by Salahuddin H et al. published in the Frontiers in Neurology

https://doi.org/10.3389/fneur.2021.636682


Tags:    
Article Source : Frontiers in neurology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News